These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
385 related articles for article (PubMed ID: 23715154)
1. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Liu Y; Marks K; Cowley GS; Carretero J; Liu Q; Nieland TJ; Xu C; Cohoon TJ; Gao P; Zhang Y; Chen Z; Altabef AB; Tchaicha JH; Wang X; Choe S; Driggers EM; Zhang J; Bailey ST; Sharpless NE; Hayes DN; Patel NM; Janne PA; Bardeesy N; Engelman JA; Manning BD; Shaw RJ; Asara JM; Scully R; Kimmelman A; Byers LA; Gibbons DL; Wistuba II; Heymach JV; Kwiatkowski DJ; Kim WY; Kung AL; Gray NS; Root DE; Cantley LC; Wong KK Cancer Discov; 2013 Aug; 3(8):870-9. PubMed ID: 23715154 [TBL] [Abstract][Full Text] [Related]
2. The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer. Kim J; Lee HM; Cai F; Ko B; Yang C; Lieu EL; Muhammad N; Rhyne S; Li K; Haloul M; Gu W; Faubert B; Kaushik AK; Cai L; Kasiri S; Marriam U; Nham K; Girard L; Wang H; Sun X; Kim J; Minna JD; Unsal-Kacmaz K; DeBerardinis RJ Nat Metab; 2020 Dec; 2(12):1401-1412. PubMed ID: 33257855 [TBL] [Abstract][Full Text] [Related]
3. CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells. Kim J; Hu Z; Cai L; Li K; Choi E; Faubert B; Bezwada D; Rodriguez-Canales J; Villalobos P; Lin YF; Ni M; Huffman KE; Girard L; Byers LA; Unsal-Kacmaz K; Peña CG; Heymach JV; Wauters E; Vansteenkiste J; Castrillon DH; Chen BPC; Wistuba I; Lambrechts D; Xu J; Minna JD; DeBerardinis RJ Nature; 2017 Jun; 546(7656):168-172. PubMed ID: 28538732 [TBL] [Abstract][Full Text] [Related]
4. Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach. Caiola E; Falcetta F; Giordano S; Marabese M; Garassino MC; Broggini M; Pastorelli R; Brunelli L J Exp Clin Cancer Res; 2018 Dec; 37(1):302. PubMed ID: 30514331 [TBL] [Abstract][Full Text] [Related]
5. LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition. Mahoney CL; Choudhury B; Davies H; Edkins S; Greenman C; Haaften Gv; Mironenko T; Santarius T; Stevens C; Stratton MR; Futreal PA Br J Cancer; 2009 Jan; 100(2):370-5. PubMed ID: 19165201 [TBL] [Abstract][Full Text] [Related]
6. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Carretero J; Shimamura T; Rikova K; Jackson AL; Wilkerson MD; Borgman CL; Buttarazzi MS; Sanofsky BA; McNamara KL; Brandstetter KA; Walton ZE; Gu TL; Silva JC; Crosby K; Shapiro GI; Maira SM; Ji H; Castrillon DH; Kim CF; García-Echeverría C; Bardeesy N; Sharpless NE; Hayes ND; Kim WY; Engelman JA; Wong KK Cancer Cell; 2010 Jun; 17(6):547-59. PubMed ID: 20541700 [TBL] [Abstract][Full Text] [Related]
7. Energizing the search to target LKB1-mutant tumors. Marcus AI; Khuri FR Cancer Discov; 2013 Aug; 3(8):843-5. PubMed ID: 23928772 [TBL] [Abstract][Full Text] [Related]
9. PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer. Long LL; Ma SC; Guo ZQ; Zhang YP; Fan Z; Liu LJ; Liu L; Han DD; Leng MX; Wang J; Guo XJ; Tan JL; Cai XT; Lin Y; Pan X; Wu DH; Bai X; Dong ZY Cancer Res; 2023 Feb; 83(4):568-581. PubMed ID: 36512628 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Shimamura T; Chen Z; Soucheray M; Carretero J; Kikuchi E; Tchaicha JH; Gao Y; Cheng KA; Cohoon TJ; Qi J; Akbay E; Kimmelman AC; Kung AL; Bradner JE; Wong KK Clin Cancer Res; 2013 Nov; 19(22):6183-92. PubMed ID: 24045185 [TBL] [Abstract][Full Text] [Related]
11. The AMPK-Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive Effects of LKB1 in NSCLC. Hollstein PE; Eichner LJ; Brun SN; Kamireddy A; Svensson RU; Vera LI; Ross DS; Rymoff TJ; Hutchins A; Galvez HM; Williams AE; Shokhirev MN; Screaton RA; Berdeaux R; Shaw RJ Cancer Discov; 2019 Nov; 9(11):1606-1627. PubMed ID: 31350328 [TBL] [Abstract][Full Text] [Related]
12. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer. Wang Y; Li N; Jiang W; Deng W; Ye R; Xu C; Qiao Y; Sharma A; Zhang M; Hung MC; Lin SH Clin Cancer Res; 2018 Nov; 24(22):5744-5756. PubMed ID: 30068711 [No Abstract] [Full Text] [Related]
14. Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors. Bhatt V; Lan T; Wang W; Kong J; Lopes EC; Wang J; Khayati K; Raju A; Rangel M; Lopez E; Hu ZS; Luo X; Su X; Malhotra J; Hu W; Pine SR; White E; Guo JY Cell Death Dis; 2023 Jan; 14(1):61. PubMed ID: 36702816 [TBL] [Abstract][Full Text] [Related]
15. LKB1 Loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT. Kaufman JM; Amann JM; Park K; Arasada RR; Li H; Shyr Y; Carbone DP J Thorac Oncol; 2014 Jun; 9(6):794-804. PubMed ID: 24828662 [TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma. Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507 [TBL] [Abstract][Full Text] [Related]
17. Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma. Liu Y; Li Y; Wang X; Liu F; Gao P; Quinn MM; Li F; Merlino AA; Benes C; Liu Q; Gray NS; Wong KK Cancer Res; 2017 Sep; 77(18):5068-5076. PubMed ID: 28754670 [TBL] [Abstract][Full Text] [Related]
18. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer. Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612 [TBL] [Abstract][Full Text] [Related]